ABSTRACT
Objective To observe the clinical efficacy of Huajian-Badu membrane in the treatment of moderate and severe cancer pain. Methods The 80 malignant tumor patients with moderate to severe cancer pain from January 2016 to June 2017 in Tianjin University of Traditional Chinese Medicine First Teaching Hospital were recruited and randomly divided into the observation group and the control group, each of 40 cases. The control group were treated with Oxycodone Hydrochloride Prolonged-release Tablets, while the treatment group were treated with Huajian-Badu membrane on the basis of the treatment in control group. The pain relief, pain frequency, morphine consumption and quality of life (Karnofsky score), adverse reaction were evaluated between two groups before and after treatment. Results Compared with the control group, the total efficiency in the observation group was significantly higher (95.0％ vs. 80.0％, χ2=4.114, P=0.043). The frequency of breakthrough pain of two groups increased on the seventh and fourteenth treatment days(0.3 ± 0.6 times vs. 0.8 ± 0.7 times, t=-3.430 and 0.4 ± 0.6 times vs. 0.9 ± 0.8 times, t=-3.162), but the number of outbreaks of pain in the observation group significantly less than the control group (P<0.05 or P<0.01). The morphine injection dosage increased on the seventh and fourteenth treatment days (3.01 ± 4.28 g vs. 5.62 ± 6.37 g, t=-2.151 and 3.21 ± 4.32 g vs. 7.84 ± 7.76 g, t=-3.297), but the amount of the observtation group was significantly lower than that of control group (P<0.05 or P<0.01). The KPS score in the observation group increased significantly, and significantly higher than the control group on the seventh and fourteenth treatment days (73.0 ± 15.0 vs. 66.0 ± 12.0, t=2.305 and 77.0 ± 13.0 vs. 70.0 ± 15.0, t=2.230, P<0.05). The adverse reaction rate of the control group was 25％, while the the observation group was 20％. The difference between two groups was significant (χ2=0.287, P=0.592). Conclusions The Huajian-Badu membrane combined Oxycodone Hydrochloride Prolonged-release Tablets can improve the total effective rate of pain relief, reduce the number of outbreaks, reduce morphine consumption, improve patient KPS score of the patients with cancer pain.
ABSTRACT
Objective@#To observe the efficacy and adverse effect of oxycodone hydrochloride prolonged-release tablets rectal administration in the treatment of cancer pain.@*Methods@#From July 2016 to July 2017, eighty patients with cancer pain in the Second People's Hospital of Jiandewere selected in the research.The patients were randomly divided into control group and observation group according to the digital table, with 40 cases in each group.The two groups were treated with oxycodone hydrochloride prolonged-release tablets, the control group was treated by oral administration, while the observation group was treated by rectal administration.At different time points after administration, the degree of pain(NRS) score, pain remission rate, quality of life before and after treatment, the incidence of adverse reactions were compared between the two groups.@*Results@#After the administration of 1 h, 3 h, the NRS scores of the observation group were (4.49±1.25)points, (3.80±1.13)points, which were lower than those of the control group[(5.56±1.42)points, (5.04±1.10)points], the differences were statistically significant(t=3.58, 4.97, all P<0.05). After administration of 1 d, 1 week and 2 weeks, the NRS scores between the two groups showed no statistically significant difference(P>0.05). The pain relief rate of the observation group was 92.50%, which was significantly higher than 75.00% of the control group, the difference was statistically significant(χ2=4.50, P<0.05). The indicators of quality of life in the observation group were significantly better than those in the control group, the differences were statistically significant(t=2.09, 2.20, 3.16, 3.28, all P<0.05). The incidence rate of adverse reaction of the observation group was 12.50%, which of the control group was 10.00%, there was no statistically significant difference between the two groups(P>0.05).@*Conclusion@#The analgesia effect of oxycodone hydrochloride prolonged-release tablets by rectal administration is similar with oral administration for cancer pain patients, and has less adverse reaction, high safety, and it is worthy of popularization and application.
ABSTRACT
Objective: To investigate the efficacy and safety of oxycodone hydrochloride prolonged-release tablets and tramadol hydrochloride sustained-release tablets in the treatment of moderate cancer pain. Methods:Totally 290 cases of the patients with mod-erate pain were divided into the observation group with 148 cases and the control group with 142 cases. The observation group received oxycodone hydrochloride prolonged-release tablets, while the control group was given tramadol hydrochloride sustained-release tablets. The treatment course was 2 weeks, and the total efficiency and the incidence of adverse drug reactions( ADR) in the two groups were calculated and compared. Results:The total efficiency in the observation group and the control group was 92. 6% and 81. 7%, respec-tively, and the difference was statistically significant (P0.05). Conclusion: The effect of oxycodone hydrochloride prolonged-release tablets in the treatment of moderate cancer pain is better than that of tramadol hydrochloride sustained-release tablets.